LONG-TERM TREATMENT WITH ONCE-WEEKLY APRAGLUTIDE REDUCES PARENTERAL SUPPORT VOLUME AND INCREASES CLINICAL RESPONDER RATES IN PATIENTS WITH SHORT BOWEL SYNDROME AND INTESTINAL FAILURE